Excyte Biopharma is the lead sponsor of 6 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are YK012 and YKST02. The most-studied condition is Primary Membranous Nephropathy.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Study of YK012 in Primary Membranous Nephropathy
NCT06982729 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy
Drug: YK012 |
Phase 1 | Recruiting | 2025-03 | China |
|
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689 · ClinicalTrials.gov ↗ · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Drug: YK012 |
Phase 1 | Recruiting | 2023-05 | China |
|
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
Drug: YK012 |
Phase 1/2 | Recruiting | 2024-09 | China |
|
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)
Drug: YK012 |
Phase 1/2 | Recruiting | 2025-08 | China |
|
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma
Drug: YKST02 |
Phase 1 | Recruiting | 2024-06 | China |
|
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
NCT07695740 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM)
Drug: YKST02 |
Phase 2 | Not yet open | 2026-09 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 6 | 5 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| First Affiliated Hospital, Sun Yat-Sen University | 2 |
| Shanghai Jiaolian Drug Research and Development | 2 |
| BioRay Pharmaceutical | 2 |
| Climb Bio | 1 |
| Shenzhen Fosun Kairos Biotechnology | 1 |
Sponsors with the most current trials registered for this condition.
Excyte Biopharma is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are YK012 (4) and YKST02 (2). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.